2023-12-13 08:20:13 ET
DENVER, Colo., Dec 13, 2023 ( www.247marketnews.com )- ReShape Lifesciences (NASDAQ: RSLS) stated, this morning, that the U.S. Food and Drug Administration (FDA) granted PMA supplement approval its next generation, enhanced Lap-Band 2.0 FLEX, and the Company is initiating its U.S. product launch.
ReShape Lifesciences is trading at $$0.3535, up $0.1025 (+40.84%), on 12.3M shares traded.
Its 52-week range is $0.1856 to $22.40. This is trading at two-month highs and is on track to eclipse its reported 13.01M shares in the float.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MNâ€) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an …
The post Listing about to Churn Its Share Float after Receiving FDA PMA Supplement Approval appeared first on 24/7 Market News .
For further details see:
Listing about to Churn Its Share Float after Receiving FDA PMA Supplement Approval
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of ReShape Lifesciences Inc. (RSLS) and does not buy, sell, or trade any shares of (RSLS). This article does not provide a professional analysis of a (RSLS) financial position. (RSLS) financial position and all other information regarding the featured Company should be verified directly with (RSLS). Please read our full disclaimer for more detailed information.
